The Lung Cancer Surgery Market size was estimated at USD 6.94 billion in 2025 and expected to reach USD 7.60 billion in 2026, at a CAGR of 10.82% to reach USD 14.25 billion by 2032.

Lung cancer surgery remains a critical curative-intent intervention for early-stage non-small cell lung cancer and selected advanced cases managed through multimodal care. The field is being reshaped by earlier detection, refined staging, minimally invasive thoracic surgery, enhanced recovery pathways, and closer integration with immunotherapy, targeted therapy, radiation oncology, pulmonology, pathology, and interventional radiology. Surgical approaches such as lobectomy, segmentectomy, wedge resection, sleeve resection, and pneumonectomy are increasingly selected through individualized assessment of tumor biology, pulmonary reserve, lymph node status, frailty, and patient preference. Evidence from contemporary thoracic oncology practice supports the movement toward parenchyma-sparing surgery in carefully selected small peripheral tumors, while systematic lymph node evaluation remains central to accurate staging and treatment planning. Robotic-assisted thoracic surgery and video-assisted thoracoscopic surgery are reducing surgical trauma in eligible patients, helping shorten hospital stays, reduce postoperative pain, and support faster functional recovery when delivered by experienced multidisciplinary teams. At the same time, rising adoption of lung cancer screening using low-dose computed tomography is increasing the identification of smaller, operable lesions, particularly among high-risk populations. The strongest opportunities in lung cancer surgery are tied to precision patient selection, perioperative safety, operating room efficiency, evidence-based standardization, and long-term survivorship management.

The lung cancer surgery landscape is undergoing transformative change as clinical practice moves from one-size-fits-all resection toward risk-adapted, biology-informed treatment pathways. Earlier diagnosis through low-dose CT screening is increasing the proportion of nodules and stage I cancers considered for surgical evaluation, while advances in imaging, bronchoscopy, endobronchial ultrasound, molecular diagnostics, and intraoperative navigation are improving preoperative planning. Minimally invasive techniques, including video-assisted and robotic-assisted thoracic surgery, are expanding access to lobectomy and segmentectomy with reduced chest wall trauma compared with open thoracotomy in appropriate cases. Sublobar resection has gained renewed relevance for selected small peripheral non-small cell lung cancers, particularly when balanced against pulmonary function preservation and long-term recurrence risk. Perioperative oncology is another major shift: neoadjuvant chemoimmunotherapy and adjuvant targeted therapies are changing surgical timing, resectability discussions, and pathologic response assessment. Enhanced recovery after surgery protocols, smoking cessation programs, prehabilitation, improved anesthesia, regional pain control, and postoperative pulmonary rehabilitation are reducing complications and supporting earlier mobilization. Together, these shifts are raising the strategic importance of multidisciplinary tumor boards, standardized surgical quality metrics, real-world outcomes tracking, and equitable referral pathways so that eligible patients reach specialist thoracic surgical care before disease progression limits curative options.

Artificial intelligence is becoming an important enabling layer across the lung cancer surgery pathway, from screening and diagnosis to operative planning, workflow optimization, and postoperative monitoring. In imaging, AI-assisted tools are being developed to help detect pulmonary nodules on low-dose CT, compare interval growth, support volumetric assessment, and reduce variability in radiology workflows. In preoperative decision-making, machine learning models are being explored to estimate operative risk, predict postoperative pulmonary complications, assess frailty-related vulnerability, and support selection between lobectomy, segmentectomy, stereotactic radiation, or nonsurgical management when clinical equipoise exists. AI-enabled radiomics and digital pathology are also being investigated for their ability to correlate imaging patterns, histology, lymph node involvement, molecular alterations, and treatment response. In the operating room, robotic platforms, computer-assisted planning, and image-guided navigation are contributing to greater procedural precision, although clinical value depends on surgeon expertise, data quality, governance, and validated outcomes. Postoperatively, AI can support early warning systems for deterioration, readmission risk stratification, and personalized follow-up scheduling. The cumulative impact is not replacement of thoracic surgeons, but augmentation of multidisciplinary decision-making. To realize durable benefit, health systems must address algorithm transparency, bias mitigation, interoperability, cybersecurity, regulatory compliance, and prospective validation in diverse patient populations.

Asia-Pacific is experiencing rising demand for lung cancer surgery as several countries face high lung cancer incidence, large smoking-exposed populations, air pollution exposure, and expanding diagnostic capacity. Japan, South Korea, China, Australia, and India are advancing minimally invasive thoracic surgery, robotic programs, and screening-linked early detection at different levels of maturity, with urban tertiary centers often leading adoption. North America remains a highly developed lung cancer surgery environment, supported by established low-dose CT screening recommendations for high-risk adults, broad availability of thoracic oncology specialists, mature robotic and video-assisted surgery programs, and strong use of multidisciplinary tumor boards. Latin America shows improving access to thoracic oncology services in major urban hospitals, with Brazil and Mexico increasingly emphasizing earlier diagnosis, pathology capability, and referral coordination, although access disparities persist between public and private care settings and between metropolitan and rural areas. Europe benefits from strong guideline-driven care, cancer control programs, national screening pilots or implementation initiatives in several countries, and advanced thoracic surgical training, with Germany, France, Italy, Spain, and the United Kingdom contributing to adoption of minimally invasive and parenchyma-sparing procedures. The Middle East is strengthening specialized cancer centers, robotic surgery infrastructure, and international clinical collaboration, particularly in Gulf countries, while tobacco control and screening awareness remain important public health priorities. Africa faces the most pronounced access barriers, including late-stage presentation, limited screening availability, constrained thoracic surgical capacity, and pathology infrastructure gaps, yet regional referral centers and cancer control planning are creating foundations for improved surgical access and earlier diagnosis.

ASEAN countries present a diverse lung cancer surgery landscape in which Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines vary widely in screening adoption, surgical infrastructure, and access to thoracic oncology expertise; the region’s priorities include earlier diagnosis, capacity building, smoking cessation, and referral efficiency. The GCC is advancing specialized cancer care through investment in tertiary hospitals, robotic surgical systems, international accreditation, and multidisciplinary oncology programs, with lung cancer surgery increasingly integrated into broader national health transformation plans. The European Union is strongly influenced by evidence-based clinical guidelines, cross-border research collaboration, health technology assessment, and policy attention to cancer screening, quality assurance, and reducing inequities between member states. BRICS countries collectively represent a large and clinically diverse patient base, with China and India carrying substantial disease burden, Brazil and South Africa working to expand access across heterogeneous health systems, and Russia maintaining established thoracic surgical capability in major centers; across the group, the central challenge is scaling early detection and specialist access. G7 countries generally demonstrate advanced thoracic surgery ecosystems, including high use of minimally invasive techniques, robust academic training networks, integrated cancer centers, and established pathways for perioperative systemic therapy. NATO member countries, many of which overlap with high-income North American and European health systems, benefit from developed hospital infrastructure and clinical standardization, while defense-related medical innovation, trauma surgery expertise, and cross-institutional training may indirectly support surgical systems, anesthesia, critical care, and postoperative recovery capabilities relevant to complex thoracic surgery.

The United States has one of the most developed lung cancer surgery ecosystems, supported by established screening recommendations, high procedural specialization, extensive robotic and video-assisted thoracic surgery adoption, and multidisciplinary cancer center networks, though screening uptake and rural access remain uneven. Canada emphasizes publicly funded cancer care, provincial screening initiatives, centralized thoracic oncology expertise, and guideline-based surgical pathways, with access influenced by geography and operating room capacity. Mexico is improving thoracic oncology services in major cities, while earlier diagnosis, pathology access, and timely referral remain key priorities. Brazil has advanced thoracic surgery capabilities in leading centers and growing use of minimally invasive techniques, but regional disparities affect access to curative-intent care. The United Kingdom is focused on rapid diagnostic pathways, lung health checks, national audit, and multidisciplinary decision-making to improve operability and outcomes. Germany combines strong hospital infrastructure, specialist surgical training, and advanced imaging and interventional pulmonology, supporting complex lung resections and minimally invasive adoption. France maintains guideline-driven thoracic oncology care, screening research, and strong integration of surgery with systemic therapy and radiation oncology. Russia has established thoracic surgical expertise in major academic and regional centers, with access varying by geography and diagnostic timeliness. Italy and Spain have mature thoracic surgery communities, broad use of multidisciplinary care, and increasing emphasis on minimally invasive resection and enhanced recovery. China faces a high lung cancer burden and is rapidly expanding screening, robotic surgery, molecular diagnostics, and thoracic surgical capacity in major hospitals. India is strengthening cancer center networks and minimally invasive expertise, while late presentation and uneven access remain major barriers. Japan is a global leader in early-stage lung cancer management, sublobar resection research, imaging surveillance, and minimally invasive thoracic surgery. Australia benefits from organized cancer care, low-dose CT screening policy momentum, specialist thoracic services, and strong quality frameworks. South Korea has advanced screening infrastructure, high-volume thoracic centers, robotic surgery capability, and strong integration of imaging, pathology, and perioperative oncology.

Industry leaders should prioritize integrated lung cancer surgery pathways that shorten the time from suspicious imaging to specialist evaluation, tissue diagnosis, staging, and treatment. Health systems and surgical programs should expand multidisciplinary tumor boards, standardize evidence-based criteria for lobectomy versus segmentectomy, and strengthen access to systematic lymph node assessment. Investments in minimally invasive and robotic-assisted surgery should be paired with surgeon training, case-volume planning, credentialing, outcomes measurement, and cost-effectiveness review. Organizations should build screening-to-surgery referral pipelines, particularly for high-risk populations, underserved communities, and regions with delayed diagnosis. Prehabilitation, smoking cessation, nutritional optimization, pulmonary rehabilitation, and enhanced recovery protocols should be embedded into routine perioperative care to reduce complications and improve patient experience. Leaders should also integrate molecular testing and perioperative systemic therapy planning into surgical workflows, as neoadjuvant and adjuvant strategies increasingly affect timing and resectability. AI adoption should be governed through validated clinical use cases, data interoperability, bias monitoring, cybersecurity, and clinician oversight. Finally, stakeholders should track quality indicators such as margin status, nodal evaluation, conversion rates, complication rates, readmissions, length of stay, patient-reported outcomes, and long-term recurrence surveillance to ensure continuous improvement without compromising safety or equity.

This executive summary is developed from verified secondary research and evidence-based synthesis of publicly available medical, clinical, regulatory, and policy sources. The methodology emphasizes peer-reviewed thoracic oncology literature, international and national clinical guidelines, cancer registry publications, public health screening recommendations, surgical quality frameworks, and health system reports. Information was evaluated for relevance to lung cancer surgery, including surgical indications, minimally invasive approaches, perioperative oncology, screening, regional access, artificial intelligence applications, and patient outcomes. Data points were cross-checked across authoritative sources where possible, with preference given to recent guideline updates, systematic reviews, randomized clinical evidence, professional society statements, and government or intergovernmental health publications. The analysis excludes market sizing, market share, revenue estimates, and forecasts, focusing instead on clinical adoption patterns, infrastructure readiness, policy direction, and strategic implications. Regional, group, and country insights were synthesized narratively to reflect differences in disease burden, screening maturity, specialist capacity, surgical technology adoption, and equity of access. The approach is designed to support decision-makers with a balanced view of evidence-backed trends while avoiding unsupported claims or promotional conclusions.

Lung cancer surgery is entering a more precise, multidisciplinary, and technology-enabled era. Earlier detection through low-dose CT screening, improved staging, minimally invasive and robotic-assisted procedures, parenchyma-sparing techniques, perioperative systemic therapy, and enhanced recovery programs are collectively improving the potential for curative-intent treatment in eligible patients. However, benefits are not evenly distributed. Access to screening, diagnostic workup, thoracic surgical expertise, molecular testing, and postoperative surveillance varies significantly across regions and health systems. Artificial intelligence, digital pathology, radiomics, and predictive analytics offer meaningful opportunities to improve detection, patient selection, risk stratification, and care coordination, but they require rigorous validation and governance. The most effective strategies will combine clinical excellence with equitable access, standardized pathways, workforce development, and continuous outcomes measurement. For healthcare leaders, the priority is clear: build integrated lung cancer surgery programs that connect prevention, screening, diagnosis, precision treatment, recovery, and survivorship. As evidence evolves, organizations that align surgical innovation with multidisciplinary care and patient-centered quality will be best positioned to improve outcomes in lung cancer treatment.